12:00 AM
Feb 25, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Glycogen synthase kinase 3 β (GSK3B); microtubule-associated protein τ (tau; MAPT; FTDP-17)


INDICATION: Alzheimer's disease (AD)

In vitro and rodent studies identified an isonicotinamide-based GSK3β inhibitor that could help treat AD or other tauopathies. Chemical synthesis of isonicotinamide analogs and testing in competitive binding assays yielded a compound that inhibited GSK3β with an IC50 of 9.8 nM and was...

Read the full 210 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >